Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,500
Employees7,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,500
Employees7,500

BIIB Key Statistics

Market cap
31.43B
Market cap31.43B
Price-Earnings ratio
23.19
Price-Earnings ratio23.19
Dividend yield
Dividend yield
Average volume
1.40M
Average volume1.40M
High today
$215.76
High today$215.76
Low today
$211.95
Low today$211.95
Open price
$215.45
Open price$215.45
Volume
225.37K
Volume225.37K
52 Week high
$219.72
52 Week high$219.72
52 Week low
$121.05
52 Week low$121.05

Stock Snapshot

With a market cap of 31.43B, Biogen(BIIB) trades at $212.86. The stock has a price-to-earnings ratio of 23.19.

On 2026-07-01, Biogen(BIIB) stock traded between a low of $211.95 and a high of $215.76. Shares are currently priced at $212.86, which is +0.4% above the low and -1.3% below the high.

Biogen(BIIB) shares are trading with a volume of 225.37K, against a daily average of 1.4M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.

In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.

BIIB News

Benzinga 2d
Biogen: Key Takeaways From Needham’s Meeting With Top Management

Spinraza HD uptake has been “quite positive,” with demand matching Spinraza’s launch levels, driven by both new and returning patients, Fadia wrote. She also ci...

Biogen: Key Takeaways From Needham’s Meeting With Top Management
TipRanks 2d
Biogen price target raised to $256 from $255 at Needham

Needham analyst Ami Fadia raised the firm’s price target on Biogen (BIIB) to $256 from $255 and keeps a Buy rating on the shares. The firm is incrementally more...

Simply Wall St 3d
Biogen Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?

Earlier this week, Biogen drew attention as Axtria honored its transformation leaders at Axtria Ignite 2026, while the company also advanced its push beyond dec...

Biogen Is Up 9.9% After US$1 Billion RayThera Deal And Salanersen Win - Has The Bull Case Changed?

Analyst ratings

58%

of 38 ratings
Buy
57.9%
Hold
36.8%
Sell
5.3%

More BIIB News

Simply Wall St 5d
Biogen Is Betting Its Next Phase Of Growth On Four New Drugs

Biogen (NasdaqGS:BIIB) is shifting its focus from older multiple sclerosis and Spinraza products to newer drugs in Alzheimer's, Friedreich’s ataxia, ALS, and de...

Biogen Is Betting Its Next Phase Of Growth On Four New Drugs
Nasdaq 5d
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?

Biogen BIIB is in the midst of a major portfolio transition. The company is seeing declining sales of its key multiple sclerosis (“MS”) drugs like Tecfidera and...

Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.